Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects.  To address these challenges, WuXi AppTec offers a full suite of nucleic acid-related services, including target validation, in vitro screening and cell-based functional assays, drug exposure analysis, biodistribution evaluation, PK/PD/efficacy testing, and safety assessment.  Leverage our comprehensive platform to accelerate …Read More >

Screen your compounds across our comprehensive cell screening panel of over 600 authenticated, validated human cancer cell lines covering 50 cancer types.  We provide single agent and combination compound screening for potency and synergy, and bioinformatics analysis for mechanistic studies and biomarker discovery related to drug responses.  We also offer an extensive KRAS mutant cell …Read More >

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis.  To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.  In addition, our in vivo metastasis panel includes a broad range of brain, bone, and liver xenograft models covering …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

As reported in Business Wire: DNA-Encoded Libraries (DELs) and NanoBRET Target Engagement Assays Accelerate Drug Discovery: “The authors demonstrate that DELs can benefit chemical biologists who require verification of live cell target engagement for their protein of interest. This is particularly beneficial for understudied protein classes that may not have existing chemical probes. Additionally, they …Read More >

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >

WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors show that LX-039 exhibits potent activity in ER degradation and proliferation assays. With favorable ADME/PK properties, LX-039 also exhibits higher efficacy in a tamoxifen-resistant MCF7 CDX model compared to fulvestrant, with up to 90% inhibition …Read More >

WuXi AppTec scientists recently contributed to a research article in Cell Chemical Biology demonstrating the successful conversion of ligands identified from DNA-encoded library (DEL) screening into highly functional, cell-active, bioluminescence resonance energy transfer (BRET) probes. The authors show that analyzing preliminary DEL hits based on target occupancy data generated in live, intact cells is an …Read More >